Vortioxetine: A meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder

Journal of Psychiatry and Neuroscience

Volumn 40, Issue 3, 2015, Pages 174-186

  Pae, Chi Un ^a,b   Wang, Sheng Min ^a   Han, Changsu ^c   Lee, Soo Jung ^a   Patkar, Ashwin A ^b   Masand, Praksh S ^d   Serretti, Alessandro ^e  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Korea University College of Medicine   (South Korea)

^d Global Medical Education Inc   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; VORTIOXETINE; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; SULFIDE;

ARTICLE; DRUG WITHDRAWAL; DSM-IV-TR; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; DEPRESSIVE DISORDER, MAJOR;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFIDES;

EID: 84928208045     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.140120     Document Type: Article

References (57)

1. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10:e1001547.
2. Papakostas GI. The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry 2010;71 Suppl E1:e03.
3. Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-59.
4. Massart R, Mongeau R, Lanfumey L. Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression. Philos Trans R Soc Lond B Biol Sci 2012;367:2485-94.
5. Malhi GS, Hitching R, Berk M, et al. Pharmacological management of unipolar depression. Acta Psychiatr Scand Suppl 2013;(443):6-23.
6. Wang SM, Han C, Lee SJ, et al. A review of current evidence for acetyll-carnitine in the treatment of depression. J Psychiatr Res 2014;53:30-7.
7. Han C, Wang SM, Seo HJ, et al. Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study. J Psychiatr Res 2014;49:75-82.
8. Han C, Wang SM, Kato M, et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother 2013;13:851-70.
9. Pae CU, Patkar AA, Jun TY, et al. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety 2007;24:522-6.
10. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence 2012;6:369-88.
11. Pae CU. Agomelatine: A new option for treatment of depression? Expert Opin Pharmacother 2014;15:443-7.
12. Marks DM. J T, Pae CU. Innovations in clinical research design and conduct in psychiatry: shifting to pragmatic approaches. Psychiatry Investig 2009;6:1-6.
13. Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig 2008;5:142-7.
14. Pae CU, Marks DM, Han C, et al. Does minocycline have antidepressant effect? Biomed Pharmacother 2008;62:308-11.
15. Gibb A, Deeks ED. Vortioxetine: first global approval. Drugs 2014;74:135-45.
16. Dubovsky SL. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder. Expert Opin Drug Metab Toxicol 2014;10:759-66.
17. Cohn LD, Becker BJ. How meta-analysis increases statistical power. Psychol Methods 2003;8:243-53.
18. Finckh A, Tramer MR. Primer: strengths and weaknesses of metaanalysis. Nat Clin Pract Rheumatol 2008;4:146-52.
19. Pae CU, Lim HK, Peindl K, et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebocontrolled clinical trials. Int Clin Psychopharmacol 2008;23:1-8.
20. Keller MB. Remission versus response: the new gold standard of antidepressant care. J Clin Psychiatry 2004;65(Suppl 4):53-9.
21. Riedel M, Moller HJ, Obermeier M, et al. Response and remission criteria in major depression–a validation of current practice. J Psychiatr Res 2010;44:1063-8.
22. Borenstein M, Hedges LV, Higgins JPT, et al. Multiple comparisons within a study. In: Introduction to meta-analysis. Hoboken (NJ): Wiley-Blackwell; 2009.
23. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
24. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012;15:589-600.
25. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012;22:482-91.
26. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014;29:138-49.
27. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012;73:953-9.
28. Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 2013;16:313-21.
29. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013;29:217-26.
30. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebocontrolled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27:215-23.
31. Jacobsen PL, Mahableshwarkar AR, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder (NCT01163266) [poster]. American Psychiatric Association 166th Annual Meeting; 2013 May 18-22; San Francisco.
32. Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A duloxetinereferenced, fixed-dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult MDD patients (NCT01153009) [poster]. American Psychiatric Association 166th Annual Meeting; 2013 May 18-22; San Francisco.
33. Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study comparing the efficacy and safety of 2 doses of vortioxetine (Lu AA21004) in acute treatment of adults with major depressive disorder (NCT01179516) [poster]. American Psychiatric Association 166th Annual Meeting; 2013 May 18-22; San Francisco.
34. Efficacy and safety study of vortioxetine (Lu AA21004) for treatment of major depressive disorder. NCT01255787. Available: http ://clinicaltrials.gov/show/NCT01255787 (accessed 2014 Apr. 1).
35. Dragheim M, Nielsen RZ. A randomized, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) switched after inadequate response to SSRI or SNRI treatment (NCT01488071) [poster]. NCDEU 53rd Annual Meeting; 2013 May 28-31; Hollywood, FL.
36. National Institute for Health and Care Excellence. Depression: the treatment and management of depression in adults. London (UK): NICE; 2009. Available: www.nice.org.uk/CG90fullguideline.pdf (accessed 2014 Feb. 8).
37. Thase ME, Larsen KG, Kennedy SH. Assessing the ‘true’ effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. Br J Psychiatry 2011;199:501-7.
38. Taylor D, Sparshatt A, Varma S, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014;348:g1888.
39. Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2012;15:417-28.
40. Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin 2008;24:1329-35.
41. Ali MK, Lam RW. Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2011;7:39-49.
42. Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007;27:672-6.
43. Schalkwijk S, Undurraga J, Tondo L, et al. Declining efficacy in controlled trials of antidepressants: effects of placebo dropout. Int J Neuropsychopharmacol 2014;17:1343-52.
44. Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 2009;24:111-8.
45. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58.
46. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009;25:161-75.
47. de Silva VA, Hanwella R. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies. Int Clin Psychopharmacol 2012;27:8-16.
48. Gartlehner G, Thaler K, Hansen RA, et al. The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis. Drug Saf 2009;​32:1159-73.
49. Huang KL, Lu WC, Wang YY, et al. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: a meta-analysis of head-tohead randomized clinical trials. Aust N Z J Psychiatry 2014;48:663-71.
50. Khin NA, Chen Y., Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 2011;72:464-72.
51. Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012;26:1408-16.
52. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012;28:1717-24.
53. Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2014;29:36-44.
54. Mann JJ. Clinical pleomorphism of major depression as a challenge to the study of its pathophysiology. World Psychiatry 2010;9:167-8.
55. Pae CU, Tharwani H, Marks DM, et al. Atypical depression: a comprehensive review. CNS Drugs 2009;23:1023-37.
56. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:664-75.
57. Lee SY, Lee SJ, Han C, et al. Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2013;46:224-35.